We are live on ! Find out more
Citadel Advisors

Citadel Advisors Portfolio holdings

AUM $618B
1-Year Est. Return 30.34%
 

Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.

This Fund
S&P 500
This Quarter Est. Return
+6.7%
1 Year Est. Return
+30.34%
3 Year Est. Return
+94.87%
5 Year Est. Return
+105.94%
10 Year Est. Return
+433.28%
AUM
$164B
AUM Growth
+$34B
Cap. Flow
+$21.1B
Cap. Flow %
12.82%
Top 10 Hldgs %
19.02%
Holding
8,908
New
1,440
Increased
3,569
Reduced
2,696
Closed
989

Sector Composition

Rank Sector Weight
1 Technology 6.08%
2 Financials 6.03%
3 Industrials 5.01%
4 Consumer Discretionary 4.73%
5 Healthcare 4.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PALI icon
7626
CALL
Palisade Bio
PALI
$330M
0
PRPH
7627
DELISTED
ProPhase Labs
PRPH
$26K ﹤0.01%
+1,182
New +$25.8K
RCG
7628
RENN Fund
RCG
$21.2M
$26K ﹤0.01%
17,250
+2,050
+13% +$2.89K
SGRP
7629
DELISTED
SPAR Group
SGRP
$26K ﹤0.01%
+21,154
New +$23.5K
SDR
7630
DELISTED
SANDRIDGE MISSISSIPPIAN TRUST II
SDR
$26K ﹤0.01%
+30,337
New +$36.1K
INFU icon
7631
InfuSystem Holdings
INFU
$184M
$25K ﹤0.01%
+10,946
New +$23.7K
LITB
7632
LightInTheBox
LITB
$58M
$25K ﹤0.01%
1,787
-292
-14% -$3.56K
CASM
7633
DELISTED
CAS Medical Systems, Inc.
CASM
$25K ﹤0.01%
+32,680
New +$23.9K
BLRX
7634
BioLineRX
BLRX
$12.3M
$24K ﹤0.01%
36
+17
+89% +$11.2K
DARE icon
7635
Dare Bioscience
DARE
$18.3M
$24K ﹤0.01%
+940
New +$30.2K
AGPU
7636
Axe Compute Inc
AGPU
$95.4M
$24K ﹤0.01%
+8
New +$34.8K
GRCE
7637
Grace Therapeutics
GRCE
$33.8M
$24K ﹤0.01%
541
-81
-13% -$5.44K
PHLT
7638
DELISTED
Performant Healthcare Inc
PHLT
$24K ﹤0.01%
+14,842
New +$26.8K
QUMU
7639
DELISTED
Qumu Corp.
QUMU
$24K ﹤0.01%
+10,614
New +$27.8K
BDR
7640
DELISTED
Blonder Tongue Laboratories Inc
BDR
$24K ﹤0.01%
+39,818
New +$19.1K
AST
7641
CALL
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
$24K ﹤0.01%
10,500
-500
-5% -$1.27K
LTBR icon
7642
Lightbridge
LTBR
$271M
$23K ﹤0.01%
1,559
+267
+21% +$3.41K
THM
7643
International Tower Hill Mines
THM
$458M
$23K ﹤0.01%
54,096
+8,041
+17% +$3.45K
BYU
7644
DELISTED
BAIYU Holdings, Inc. Common Stock
BYU
$23K ﹤0.01%
+13
New +$48.1K
ATIS
7645
DELISTED
Attis Industries Inc. Common Stock
ATIS
$23K ﹤0.01%
2,726
+765
+39% +$7.11K
CVRS
7646
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
$23K ﹤0.01%
+22,980
New +$26K
YGE
7647
PUT
DELISTED
Yingli Green Energy Holding Comp
YGE
$23K ﹤0.01%
+13,400
New +$28.4K
FCRE
7648
DELISTED
FC Global Realty Incorporated Common Stock
FCRE
$23K ﹤0.01%
+24,634
New +$27.2K
PRPO icon
7649
Precipio
PRPO
$38.7M
$22K ﹤0.01%
+61
New +$27.5K
SEEL
7650
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
0

Similar funds

Citadel Advisors's Q4 2017 Portfolio in Review

As of Q4 2017, Citadel Advisors held 8,908 positions worth $164B, up 26% from $130B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Citadel Advisors deployed $21.1B of net new capital in Q4 2017, opening 1,440 new positions and adding to 3,569 existing holdings. Its largest new stake was Celgene Corp: 3,708,916 shares worth $387M.

By sector, the portfolio is most concentrated in Technology at 6.1% of assets, down from 7% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Goldman Sachs, an estimated $441M trimmed.

  • Citadel Advisors's largest Q4 2017 buy was Celgene Corp: 3,708,916 shares worth $387M.
  • Citadel Advisors added most to State Street SPDR S&P 500 ETF Trust in Q4 2017, an estimated $1.16B increase.
  • Citadel Advisors's biggest Q4 2017 reduction was Goldman Sachs, cutting an estimated $441M.
  • Citadel Advisors fully exited CR Bard Inc. in Q4 2017, selling an estimated $209M.
  • Citadel Advisors's ten largest holdings make up 19% of its $164B portfolio in Q4 2017.
  • Citadel Advisors opened 1,440 new positions and closed 989 in Q4 2017.
  • Citadel Advisors's portfolio value rose 26% quarter-over-quarter to $164B.

Based on Citadel Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.